Structure Therapeutics Files 8-K
Ticker: GPCR · Form: 8-K · Filed: Dec 17, 2024 · CIK: 1888886
| Field | Detail |
|---|---|
| Company | Structure Therapeutics Inc. (GPCR) |
| Form Type | 8-K |
| Filed Date | Dec 17, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, corporate-disclosure
TL;DR
Structure Therapeutics filed a routine 8-K, no major news.
AI Summary
Structure Therapeutics Inc. filed an 8-K on December 17, 2024, reporting on financial statements and exhibits. The company, formerly known as ShouTi Inc. until October 19, 2021, is incorporated in the Cayman Islands and operates in the Pharmaceutical Preparations industry. The filing does not disclose specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This filing serves as a standard corporate disclosure, indicating the company is meeting its reporting obligations with the SEC.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for financial statements and exhibits, not indicating any new risks or material changes.
Key Players & Entities
- Structure Therapeutics Inc. (company) — Registrant
- ShouTi Inc. (company) — Former company name
- December 17, 2024 (date) — Date of earliest event reported
- October 19, 2021 (date) — Date of name change
- Cayman Islands (jurisdiction) — State of incorporation
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on financial statements and exhibits as required by the SEC.
What was Structure Therapeutics Inc. previously known as?
Structure Therapeutics Inc. was previously known as ShouTi Inc.
When did the company change its name from ShouTi Inc. to Structure Therapeutics Inc.?
The company changed its name from ShouTi Inc. on October 19, 2021.
In which jurisdiction is Structure Therapeutics Inc. incorporated?
Structure Therapeutics Inc. is incorporated in the Cayman Islands.
What is the SIC code for Structure Therapeutics Inc.?
The Standard Industrial Classification (SIC) code for Structure Therapeutics Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 564 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-12-17 16:16:05
Key Financial Figures
- $0.0001 — enting three ordinary shares, par value $0.0001 per ordinary share GPCR Nasdaq Glo
Filing Documents
- tm2431274d1_8k.htm (8-K) — 33KB
- tm2431274d1_ex99-1.htm (EX-99.1) — 18KB
- tm2431274d1_ex99-1img001.jpg (GRAPHIC) — 6KB
- 0001104659-24-129378.txt ( ) — 287KB
- gpcr-20241217.xsd (EX-101.SCH) — 4KB
- gpcr-20241217_def.xml (EX-101.DEF) — 27KB
- gpcr-20241217_lab.xml (EX-101.LAB) — 36KB
- gpcr-20241217_pre.xml (EX-101.PRE) — 25KB
- tm2431274d1_8k_htm.xml (XML) — 6KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On December 17, 2024, Structure Therapeutics Inc. (the "Company") issued a press release announcing the selection of its lead oral small molecule amylin receptor agonist, ACCG-2671, for the treatment of obesity. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated December 17, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Structure Therapeutics Inc. Date: December 17, 2024 By: /s/ Raymond Stevens Raymond Stevens, Ph.D. Chief Executive Officer